Stay updated on Pembrolizumab Combo in Advanced Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Advanced Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Advanced Ovarian Cancer Clinical Trial page
- Check2 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0; the study page remains an error page.SummaryDifference0.2%

- Check9 days agoChange DetectedA sitewide banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to updates and FAQs.SummaryDifference1%

- Check16 days agoChange DetectedThe ClinicalTrials.gov footer revision label changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check23 days agoChange DetectedThe ClinicalTrials.gov page remains a 403 Forbidden error page, with the footer revision changing from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check44 days agoChange DetectedThe study record page now shows a 403 Forbidden error, replacing the detailed study information with an access-denied message. As a result, the core content and navigation are no longer visible.SummaryDifference21%

- Check64 days agoChange DetectedThe page revision label was updated from v3.6.5 to v3.6.6. This indicates a new build or update to the page documentation.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab Combo in Advanced Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Advanced Ovarian Cancer Clinical Trial page.